‘Pervasive abuse’ of patent system at root of drug pricing crisis: I-MAK
Report found that four times as many patents are granted on the top ten drugs in the US, compared to Europe | Non-profit says that the US’ patent system is ‘broken’.
Swiss watchdog investigates Novartis over patent use
Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition
MPP inks deal with French pharma firm to fight malaria in low-income countries
Malaria remains endemic in 91 countries representing half of the world’s population | Licence is key to allow rapid access to innovation for those who need it most.
McGuireWoods gains two life sciences patent litigators
Law firm McGuire Woods has hired IP litigators Michael Nutter and Merritt Westcott, for its Chicago and Houston offices, respectively.
US company secures genetically modified rice ban against Chinese rival
Kansas-based company wins block on infringing plant-based albumins | Genetically programmed rice expresses human proteins used in immunotherapy drugs, gene therapies and vaccines.
EIP unveils life sciences hub in Scandinavia
Patent law firm EIP has opened a new regional hub in Stockholm, Sweden with a focus on the life sciences.
Microsoft partners with Nordic data science firm on AI project
Deal set to enable faster use of artificial intelligence in drug discovery | Planned AI models to identify novel targets and establish biomarkers of disease.
Big pharma firm settles HIV drug disputes with generic makers
Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.
Generic maker urges review of $235m skinny label decision
A split Federal Circuit revived a 2017 jury verdict that Teva had infringed GSK drug | Israeli pharma firm warns of threat to availability of low-cost generic medicines.
Hogan Lovells adds tech partner to Boston office
Law firm Hogan Lovells has hired Chris Natkanski to its global regulatory and intellectual property, media, and technology practice group in Boston.
